ERBB2 and esophageal cancer: The combination of the parbocizumab antibody, trastuzumab, and first-line chemotherapy substantially extended the progression-free survival in patients with metastatic HER2-positive gastric or esophageal cancer, particularly in those with a tumor PD-L1 composite positive score greater than or equal to 1 [227].